Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been ...

北京协和医院血液内科团队开展的一项前瞻性临床研究发现，对于复发/难治性温抗体型自身免疫性溶血性贫血，采用利妥昔单抗联合硼替佐米治疗起效快，安全性良好，可以显著减少患者对于激素的依赖。近日，该研究成果发表在中科院1区杂志American Journal ...

研究涉及30名复发/难治性wAIHA患者，结果显示，86.7%的患者在首次联合治疗后获得了应答，中位起效时间仅为15天。六个月时，总有效率高达80.0%，完全缓解率达到56.7%。更令人振奋的是，76.7%的患者在治疗后成功降低了对糖皮质激素的依赖，许多患者也显著减少了输血的需求。这一成果在中科院1区杂志American Journal of ...

传统的治疗方案主要依赖利妥昔单抗，这种药物通过靶向清除自身反应性B细胞来治疗自身免疫疾病，然而起效时间相对较慢，且长期稳定的患者仅有50%。在此次研究中，研究团队发现，硼替佐米的加入可以靶向清除产生自身抗体的浆细胞，从而加速起效并提高治疗有效率。

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received ...

which is in a phase 3 trial as a treatment for IgG4-related disease (IgG4-RD), phase 2/3 in warm autoimmune haemolytic anaemia (wAIHA), and phase 2 in multiple sclerosis (MS) and systemic lupus ...

such as warm autoimmune hemolytic anemia (wAIHA), before potentially moving to dermatologic indications, such as hidradenitis suppurativa (HS), and neurologic indications, such as multiple sclerosis ...

MULTIPLE MYELOMA (MM), an incurable blood cancer, remains a major challenge in oncology, with a pressing need for novel treatment strategies. A new study has identified a significant metabolic ...

SAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...